Changes Afoot: 2022 Outlook for Pharma and its People
Pharmaceutical Technology Europe
; 34(1):10-13, 2022.
Artigo
em Inglês
| ProQuest Central | ID: covidwho-20243764
ABSTRACT
[...]we've seen more companies diversifying their portfolios and investing in therapies for rare diseases so that advanced therapies, and in particular, gene therapies-which were deemed experimental and risky when I was involved with the European Medicines Agency's Committee for Advanced Therapies some 10-12 years ago-take centre stage," Schneider continues. The year's expectations were unsurprisingly centred around COVID-19 for Martin Lush, global vice president. "Many big pharma companies will continue down the path of externalising services for small molecules and/or known molecules maintenance, to keep their focus on novel molecules," she explains. [...]of this complexity, there can be much negotiation and, hence, delay in access to medicines, he explains.
Buscar no Google
Coleções:
Bases de dados de organismos internacionais
Base de dados:
ProQuest Central
Tipo de estudo:
Estudo prognóstico
Idioma:
Inglês
Revista:
Pharmaceutical Technology Europe
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS